Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis

Journal of Clinical Pharmacology

Volumn 56, Issue 5, 2016, Pages 628-636

  Wang, Xiaoli ^a   Tirucherai, Giridhar ^a   Marbury, Thomas C ^b   Wang, Jessie ^a   Chang, Ming ^a   Zhang, Donglu ^a   Song, Yan ^a   Pursley, Janice ^a   Boyd, Rebecca A ^c   Frost, Charles ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b ORLANDO CLINICAL RESEARCH CENTER   (United States)

^c PFIZER INC   (United States)

Author keywords

apixaban; end stage renal disease; hemodialysis; pharmacodynamics; pharmacokinetics

Indexed keywords

APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 10A; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SAFETY; DRUG TOLERABILITY; ELIMINATION HALF-LIFE; END STAGE RENAL DISEASE; FEMALE; HEADACHE; HEMODIALYSIS; HUMAN; HYPOTENSION; INTERNATIONAL NORMALIZED RATIO; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; OPEN STUDY; PARTIAL THROMBOPLASTIN TIME; PHARMACODYNAMICS; PROTHROMBIN TIME; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; BLOOD; CONTROLLED CLINICAL TRIAL; KIDNEY FAILURE, CHRONIC; METABOLISM;

ADULT; AREA UNDER CURVE; FACTOR XA; FACTOR XA INHIBITORS; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; PYRAZOLES; PYRIDONES; RENAL DIALYSIS;

EID: 84952701083     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.628     Document Type: Article

References (22)

1. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P,; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010; 375 (9717): 807-815.
2. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ., Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009; 361 (6): 594-604.
3. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM., Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010; 363 (26): 2487-2498.
4. Connolly SJ, Eikelboom J, Joyner C, et al., Apixaban in patients with atrial fibrillation. N Engl J Med. 2011; 364 (9): 806-817.
5. Granger CB, Alexander JH, McMurray JJV, et al,; ARISTOTLE committees and investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365 (11): 981-992.
6. Agnelli G, Buller HR, Cohen, et al. AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013; 369 (9): 799-808.
7. Agnelli G, Buller HR, Cohen A, et al,; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013; 368 (8): 699-708.
8. Raghavan N, Frost CE, Yu Z, et al., Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009; 37 (1): 74-81.
9. Chang M, Yu Z, Byon W, et al., Effect of renal impairment on the pharmacokinetics, pharmacodynamics and safety of apixaban, J Clin Pharmacol. 2015. doi: 10.1002/jcph.633
10. Cockcroft DE, Gault MH., Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16 (1): 31-41.
11. Pursley J, Shen JX, Shuster A, et al., LC-MS/MS determination of apixaban (BMS-562247) and its major metabolite in human plasma: an application of polarity switching and monolithic HPLC column. Bioanalysis. 2014; 6: 2071-2082.
12. Velenosi TJ, Urquhart BL., Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis. Expert Opin Drug Metab Toxicol. 2014; 10: 1131-1143.
13. Barrett JC, Wang Z, Frost C, Shenker A., Clinical laboratory measurement of direct factor Xa inhibitors: Anti-FXa assay is preferable to prothrombin time assay. Thromb Haemost. 2010; 104: 1263-1271.
14. Eliquis® (apixaban tablets) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2014. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/202155s009lbl.pdf. Accessed February 9, 2015.
15. Frost C, Yu S, Nepal S, et al., Apixaban, a direct factor Xa inhibitor: single-dose pharmacokinetics and pharmacodynamics of an intravenous formulation. J Clin Pharmacol. 2008; 48: 1132.
16. Vakkalagadda B, Frost C, Wang J, et al., Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor Xa. J Clin Pharmacol. 2009; 49: 1124.
17. Frost C, Wang J, Nepal S, et al., Apixaban, an oral, direct factor Xa inhibitor: single-dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2013; 75: 476-487.
18. Frost C, Nepal S, Wang J, et al., Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol. 2013; 76: 776-786.
19. Tanaka H, Nagasawa Y, Matsui I, et al., Pharmacokinetics of olmesartan medoxomil in hemodialysis patients: little effect of dialysis upon its pharmacokinetics. Clin Exp Nephrol. 2009; 13 (1): 61-65.
20. Frost CE, Yu Z, Wang J, et al., Single-dose safety and pharmacokinetics of apixaban in subjects with mild or moderate hepatic impairment. Clin Pharmacol Ther. 2009; 85 (suppl 1): S34.
21. Upreti VV, Wang J, Barrett YC, et al., Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol. 2013; 76: 908-916.
22. Frost C, Shenker A, Gandhi MD, et al., Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. Br J Clin Pharmacol. 2014; 78: 877-885.